{"entity":{"id":"narula-gaurav","kind":"person","name":"Gaurav Narula","aka":[],"tldr":"A paediatric oncologist at Tata Memorial who led the leukaemia arm of India's first CAR-T trials and runs national childhood leukaemia protocols.","summary":"Gaurav Narula is a paediatric oncologist at Tata Memorial Hospital whose work spans childhood acute lymphoblastic leukaemia protocols adapted to Indian conditions, the Indian Childhood Collaborative Leukaemia group trials and the clinical development of talicabtagene autoleucel (NexCAR19), for which he was an investigator and an author of the published real-world series. He also works on infection control and supportive care in low-resource paediatric oncology.","asOf":"2026-09-10","links":[{"label":"Tata Memorial Centre","url":"https://tmc.gov.in"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Narula%20G%5BAuthor%5D%20Tata%20Memorial%20paediatric%20leukaemia"}],"tags":[],"related":[],"cancers":["all-leukemia"],"sections":[],"technologies":["car-t"],"targets":[],"drugs":["talicabtagene-autoleucel"],"companies":[],"institutions":["tata-memorial"],"pathways":[],"terms":[],"trials":["talicel-phase-1-2"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["indian-journal-of-cancer"],"dependsOn":[],"notes":[],"role":"Professor of Paediatric Oncology, Tata Memorial Hospital","institutionId":"tata-memorial","specialisms":["Paediatric oncology","Childhood leukaemia","CAR-T cell therapy","Cooperative group trials"],"profiles":[{"label":"Tata Memorial Centre","url":"https://tmc.gov.in"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Narula%20G%5BAuthor%5D%20Tata%20Memorial%20paediatric%20leukaemia"}],"papers":[{"title":"Clinicoepidemiological profiles, clinical practices, and the impact of holistic care interventions on outcomes of pediatric hematolymphoid malignancies - A 7-year audit of the pediatric hematolymphoid disease management group at Tata Memorial Hospital","journal":"Indian Journal of Cancer","year":2017,"doi":"10.4103/ijc.ijc_487_17"},{"title":"Treatment and follow‐up of children with chronic myeloid leukaemia in chronic phase (CML‐CP) in the tyrosine kinase inhibitor (TKI) era—Two decades of experience from the Tata Memorial Hospital paediatric CML (pCML) cohort","journal":"British Journal of Haematology","year":2023,"doi":"10.1111/bjh.19251"},{"title":"Protocol for ICiCLe-ALL-14 (InPOG-ALL-15-01): a prospective, risk stratified, randomised, multicentre, open label, controlled therapeutic trial for newly diagnosed childhood acute lymphoblastic leukaemia in India","journal":"Trials","year":2022,"doi":"10.1186/s13063-022-06033-1"},{"title":"Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: an open-label, multicentre, phase 1/2 study","journal":"Lancet Haematology","year":2025,"url":"https://doi.org/10.1016/S2352-3026(24)00377-6","doi":"10.1016/S2352-3026(24)00377-6"}],"orcid":"0000-0002-8539-295X"},"route":"/people/narula-gaurav/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"drug":[{"id":"talicabtagene-autoleucel","kind":"drug","name":"Talicabtagene autoleucel","route":"/drugs/talicabtagene-autoleucel/"}],"institution":[{"id":"tata-memorial","kind":"institution","name":"Tata Memorial Centre","route":"/institutions/tata-memorial/"}],"trial":[{"id":"talicel-phase-1-2","kind":"trial","name":"Talicabtagene autoleucel (NexCAR19) phase 1/2","route":"/trials/talicel-phase-1-2/"}],"journal":[{"id":"indian-journal-of-cancer","kind":"journal","name":"Indian journal of cancer","route":"/journals/indian-journal-of-cancer/"}],"company":[{"id":"immunoact","kind":"company","name":"ImmunoACT","route":"/companies/immunoact/"}],"paper":[{"id":"paper-jain-talicabtagene-lancet-haem-2025","kind":"paper","name":"Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: an open-label, multicentre, phase 1/2 study","route":"/key-papers/paper-jain-talicabtagene-lancet-haem-2025/"}]}}